Recent advances in scleroderma-associated pulmonary hypertension

Current Opinion in Rheumatology

Volumn 26, Issue 6, 2014, Pages 637-645

  Highland, Kristin B ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Pulmonary arterial hypertension; Pulmonary hypertension; Scleroderma; Systemic sclerosis

Indexed keywords

BIOLOGICAL MARKER; VASODILATOR AGENT;

CAPILLAROSCOPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE ASSOCIATION; DYSPNEA; EARLY DIAGNOSIS; HEART CATHETERIZATION; HUMAN; INCIDENCE; INFLAMMATION; MORBIDITY; MORTALITY; OUTCOME ASSESSMENT; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK FACTOR; SCLERODERMA; SCREENING; SURVIVAL; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT INDICATION; COMPLICATION; HYPERTENSION, PULMONARY; SYSTEMIC SCLEROSIS;

HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 84924284648     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000114     Document Type: Review

References (70)

1. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66:940-944.
2. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: anAmerican college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72:1747-1755.
3. Hoeper M, Bogaard HJ, Condliffe R, et al. Definitions and diagnosis of pulmonary hypertension. J Am Coll Cardiol 2013; 62:D42-D50.
4. Kovacs G, Berghold A, Scheidl S, Olschewski H. Pulmonary artery pressure during rest and exercise in healthy subjects: a systematic review. Eur Respir J 2009; 34:888-894.
5. Kovacs G, Maier R, Aberer E, et al. Borderline pulmonary arterial pressure is associated with decreased exercise capacity in scleroderma. Am J Respir Crit Care Med 2009; 180:881-886.
6. Bae S, Saggar R, Bolster MB, et al. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. Ann Rheum Dis 2012; 71:1335-1342.
7. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest 2012; 141:210-211.
8. Yaqub A, Chung L. Epidemiology and risk factors for pulmonary hypertension in systemic sclerosis. Curr Rheumatol Rep 2013; 14:302.
9. Mukerjee D, St. Geroge D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003; 62:1088-1103.
10. Hachulla E, Gressin V, Guillevin L, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French Nationwide prospective multicenter study. Arthritis Rheum 2005; 52:3792-3800.
11. Hachulla E, de Groote P, Gressin V, et al., Itinér AIR Sclérodermie Study Group. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60:1831-1839.
12. Avouac J, Airò P, Meune C, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and meta-analysis of 5 studies. J Rheumatol 2010; 37:2290-2298.
13. Domsic RT, Chung L, Gomberg-Maitland M, et al. Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): comparison of outcomes in subtypes of pulmonary hypertension. Arthritis Rheum 2010; 62 (10S):S245.
14. Hunzelmann N, Genth E, Krieg T, et al. The registry of the German network for systemic scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 2008; 47:1185-1192.
15. Hachulla E, Launay D, Mouthon L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest 2009; 136:1211-1219.
16. Hassoun PM, Mouthon L, Barbera JA, et al. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009; 54:S10-S19.
17. Dorfmuller P, Humbert M, Perros F, et al. Fibrous remodeling of the pulmonary venous system in pulmonary arterial hypertension associated with connective tissue diseases. Hum Pathol 2007; 38:893-902.
18. Tuder RM. Pathology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30:376-385.
19. George PM, Oliver E, Dorfmuller P, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Circ Res 20014; 114:677-688.
20. George PM, Oliver E, Dorfmuller P, et al. Evidence for the involvement of type I interferon in pulmonary arterial hypertension. Cir Res 2014; 114:677-688.
21. Lenna S, Farina AG, Martyanov V, et al. Increased expression of endoplasmic reticulum stress and unfolded protein response genes in peripheral blood mononuclear cells from patients with limited cutaneous systemic sclerosis and pulmonary arterial hypertension. Arthritis Rheum 2013; 65:1357-1366.
22. McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on ExpertConsensusDocuments and the American Heart Association developed in collaboration with the American College of Chest Physicans; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53:1573-1619.
23. Task Force for Diagnosis, Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC),European Respiratory Society (ERS), International Society of Heart, Lung Transplantation (ISHLT). Galiè N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34:1219-1263.
24. Gladue H, Steen V, Allanore Y, et al. Combination of echocardiographic and pulmonary function test measures improves sensitivity for diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of 2 cohorts. J Rheumatol 2013; 40:1706-1711.
25. Codullo V, Caporali R, Cuomo G, et al. Stress Doppler echocardiography in systemic sclerosis. Arthritis Rheum 2013; 65:2403-2411.
26. Huez S, Roufousse F, Vachiéry JL, et al. Isolated right ventricular dysfunction in systemic sclerosis: latent pulmonary hypertension? Eur Respir J 2007; 30:928-936.
27. Gargani L, Pignone A, Agoston G, et al. Clinical and echocardiographic correlations of exercise-induced pulmonary hypertension in systemic sclerosis: a multicenter study. Am Heart J 2013; 165:200-207.
28. Avouac J, Huscher D, Furst DE, et al., for the EPOSS group. Expert consensus for performing right heart catheterization for suspected pulmonary arterial hypertension in systemic sclerosis: a Delphi consensus study with cluster analysis. Ann Rheum Dis 2014; 73:191-197.
29. Woods PR, Frantz RP, Taylor BJ, et al. The usefulness of submaximal exercise gas exchange to define pulmonary arterial hypertension. J Heart Lung Transplant 2011; 30:1133-1142.
30. Yasunobu Y, Oudiz RJ, Sun XG, et al. End-tidal PCO2 abnormality and exercise limitation in patients with primary pulmonary hypertension. Chest 2005; 127:1637-1646.
31. Bernstein EJ, Mandl LA, Gordon JK, et al. Submaximal heart heart and pulmonary evaluation: a novel noninvasive test to identify pulmonary hypertension in patients with systemic sclerosis. Arthritis Care Res 2013; 65:1713-1718.
32. Zisman DA, Karlamangia AS, Ross DJ, et al. High-resolution chest CT findings do not predict the presence of pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2007; 132:773-779.
33. Devaraj A, Wells AU, Meister MG, et al. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology 2008; 249:1042-1049.
34. Zompatori M, Leone MB, Giannotta M, et al. Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography. Radiol Med 2013; 118:1360-1372.
35. McCall RK, Ravenel J, Nietert PJ, et al. Relationship of main pulmonary artery diameter to pulmonary arterial pressure in scleroderma patients with and without interstitial fibrosis. J Comput Assist Tomogr 2014; 38:163-168.
36. Riccieri V, Vasile M, Iannace N, et al. Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study. Rheumatology 2013; 42:1424-1438.
37. Mathai SC, Bueso M, Hummers LK, et al. Disproportionate elevation of Nterminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension. Eur Resp J 2010; 35:95-104.
38. McLaughlin VV, Gaine SP, Howard LS, et al. Treatment goals of pulmonary hypertension. J Am Coll Cardiol 2013; 62:073-081.
39. Ruiter G, Lanser I, de Man FS, et al. Iron deficiency in systemic sclerosis patients with and without pulmonary hypertension. Rheumatology 2014; 53:285-292.
40. Rhodes CJ, Howard LS, Busbridge M, et al. Iron deficiency and raised hepcidin in idiopathic pulmonary arterial hypertension: clinical prevalence, outcomes, and mechanistic insights. J Am Coll Cardiol 2011; 58:300-309.
41. Rhodes CJ, Wharton J, Howard L, et al. Iron deficiency in pulmonary arterial hypertension: a potential therapeutic target. Eur Respir J 2011; 38:1453-1460.
42. Eakin EG, Sassi-Dambron DE, Ries AL, Kaplan RM. Reliability and validity of dyspnea measures in patients with obstructive lung disease. Int Behav Med 1995; 2:118-134.
43. Chung L, Chen H, Khanna D, Steen VD. Dyspnea assessment and pulmonary hypertension in patients with systemic sclerosis: utility of the University of California, San Diego, Shortness of Breath Questionnaire. Arthritis Care Res 2013; 65:454-463.
44. Humbert M, Yaici A, de Groote P, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63:3522-3530.
45. Galie N, Rubin L, Hoeper M, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double blind, randomized controlled trial. Lancet 2008; 371:2093-2100.
46. Hachulla E, Launay D, Yaici A, et al. Pulmonary arterial hypertension associated with dyspnea: mild symptoms but severe outcome. Rheumatology (Oxford) 2010; 49:940-944.
47. Khanna D, Gladue H, Channick R, et al. Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. Arthritis Rheum 2013; 65:3194-3201.
48. Coghlan JG, Denton CP, Grünig E, et al. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Reum Duis 2014; 73:1340-1344.
49. Thakkar V, Stevens WM, Prior D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case control study. Arthritis Res Ther 2012; 14:R143.
50. Badesch DB, Rskob GE, Elliott CG, et al. Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest 2010; 137:376-387.
51. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprestenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132:425-434.
52. Cozzi F, Pigatto E, Rizzo M, et al. Low occurrence of digital ulcers in scleroderma patients treated with bosentan for pulmonary arterial hypertension: a retrospective case-control study. Clin Rheumatol 2013; 32:679-683.
53. Korn JH, Mayes M, Matucci-Cerinic M, et al. Digital ulcers in systemic sclerosis. Prevention by treatment with Bosentan, an oral endothelin receptor antagonist. Arthritis Rheum 2015; 50:3985-3993.
54. Matucci-Cerinic M, Denton CP, Furst DE, et al. Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 2015; 70:32-38.
55. Kumar U, Gokhle SS, Sreenivas V, et al. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosisrelated pulmonary arterial hypertension and cutaneous vascular complications. Rheumatol In 2013; 33:1047-1052.
56. Tedford RJ, Mudd JO, Girgis RE, et al. Right ventricular dysfunction in systemic sclerosis-associated pulmonary arterial hypertension. Circ Heart Fail 2013; 6:953-963.
57. Hesselstrand R, Wildt M, Ekmehag B, et al. Survival in patients with pulmonary arterial hypertension associated with systemic sclerosis from a Swedish single centre: prognosis still poor and prediction difficult. Scand J Rheumatol 2011; 40:127-132.
58. Komocsi A, Vorobcsuk A, Faludi R, et al. The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) 2012; 51:1027-1036.
59. Chung L, Domsic RT, Lingala B, et al. Survival and predictors of mortality in systemic sclerosis-associated pulmonary arterial hypertension: outcomes from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. Arthritis Care Res 2014; 66:489-495.
60. Rubenfire M, Huffman MD, Krishnan S, et al. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era. Chest 2013; 1434:1282-1290.
61. Lefè vre G, Dauchet L, Hachulla E, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension. Arthritis Rheum 2013; 65:2412-2423.
62. Giunta A, Tirri E, Maione S, et al. Right ventricular diastolic abnormalities in systemic sclerosis. Relation to left ventricular involvement and pulmonary hypertension. Ann Rheum Dis 2000; 59:94-98.
63. Lindqist P, Caidahl K, Neuman-Andersen G, et al. Disturbed right ventricular diastolic function in patients with systemic sclerosis: a Doppler tissue imaging study. Chest 2005; 128:755-763.
64. Ngian GS, Stevens W, Prior D, et al. Predictors of mortality in connective tissue disease-associated pulmonary arterial hypertension: a cohort study. Arthritis Res Ther 2012; 14:R213.
65. Campo A, Mathai SC, Le Pavec J, et al. Hemodynamic predictors of survival in scleroderma-related pulmonary arterial hypertension. Am J Respir Crit Care Med 2010; 182:252-260.
66. Condliffe R, Kiely DG, Peacock AJ, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179:151-157.
67. Launay D, Sitbon O, Hachulla E, et al. Survival in systemic sclerosis-associated pulmonary arterial hypertension in the modern management era. Ann Rheum Dis 2013; 72:1940-1946.
68. Chung L, Liu J, Parsons L, et al. Characterization of connective tissue diseaseassociated pulmonary arterial hypertension from REVEAL: identifying systemic sclerosis as a unique phenotype. Chest 2010; 138:1383-1394.
69. Kiatchoosakun S, Wongvipaporn C, Nanagara R, et al. Right ventricular systolic pressure assessed by echocardiography: a predictive factor of mortality in patients with scleroderma. Clin Cardiol 2011; 34:488-493.
70. Shah AA, Chung SE, Wigley FM, et al. Changes in estimated right ventricular systolic pressure predict mortality and pulmonary hypertension in a cohort of scleroderma patients. Ann Rheum Dis 2013; 72:1136-1140.